Tolerability of high-dose interferon alfa-2b in patients with high-risk melanoma
Abstract
Despite therapeutic advances in metastatic melanoma, fundamental changes in the section of adjuvant therapy has not yet come. The problem of adjuvant therapy in cutaneous melanoma in Russia is of particular importance due to the large proportion of advanced forms of the disease in the patient population with the local and regional stages. To date, it is shown that recombinant interferon alpha-2a and alpha-2b (IFN alpha) are an effective drugs for adjuvant therapy melanoma. high-dose interferon alpha-2b (HDI) is the standard treatment in the Us in patients with IIB–III melanoma stages. In this article we consider the portability of hdI during adjuvant therapy in patients with high-risk melanoma in a specialized department.
About the Authors
A. S. Vichrova
N.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Moscow
K. V. Orlova
N.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Moscow
I. V. Samoylenko
N.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Moscow
G. Yu. Kharkevich
N.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Moscow
L. V. Demidov
N.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Moscow
References
1. Чиссов В.И., Старинский В.В., Петрова Г.В. (eds.): Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Москва: ФГБУ «МНИОИ им. П.А. Герцена» Минздравсоцразвития России. 2012.
2. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., Buzaid A.C., Cochran A.J., Coit D.G., Ding S. et al: Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009, v. 27 (36), p. 6199-6206.
3. Almazan-Fernandez F.M., Serrano-Ortega S., MorenoVillalonga J.J. Descriptive study of the costs of diagnosis and treatment of cutaneous melanoma. Actas Dermosifiliogr. 2009, v. 100 (9), p. 785-791.
4. Guy G.P. Jr., Ekwueme D.U., Tangka F.K., Richardson L.C. Melanoma treatment costs: a systematic review of the literature, 1990-2011. Am. J. Prev. Med. 2012, v. 43 (5), p. 537-545.
5. Демидов Л.В. Лечение первичной меланомы кожи. In: Global melanoma task force meeting: 15.12.2010. 2010; Москва, Ренессанс Москва Монарх 2010.
6. Демидов Л.В., Поддубная И.В., Харкевич Г.Ю., Абрамов М.Е., Анисимов В.В., Болотина Л.В., Борисов В.И., Булавина И.С., Гладков О.А., Горбунова В.А. и соавт. Адъювантное лечение меланомы кожи: российские клинические рекомендации, основанные на принципах доказательной медицины и мнении экспертов. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2011, № 22 (2), с. 3-11.
7. Алиев М.Д., Демидов Л.В. и соавт. Проект: клинические рекомендации по диагностике и лечению больных меланомой кожи. Ассоциация онкологов России. 2014.
8. Mocellin S., Pasquali S., Rossi C.R., Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2010, v. 102 (7), p. 493-501.
9. Kirkwood J.M., Manola J., Ibrahim J., Sondak V., Ernstoff M.S., Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 2004, v. 10 (5), p. 1670-1677.
10. Petrella T. Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommendations 2009. In: Evidence-based Series #8-1 Version 32009: Section 1. 2009.
11. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 1996, v. 14 (1), p. 7-17.
12. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Ernstoff M.S., Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB–III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 2001, v. 19 (9), p. 2370-2380.
13. Eggermont A.M., Suciu S., Santinami M., Testori A., Kruit W.H., Marsden J., Punt C.J., Sales F., Gore M., Mackie R. et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008, v. 372 (9633), p. 117-126.
14. Grob J.J., Dreno B., de la Salmoniere P., Delaunay M., Cupissol D., Guillot B., Souteyrand P., Sassolas B., Cesarini J.P., Lionnet S. et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998, v. 351 (9120), p. 1905-1910.
15. Wheatley K., Ives N., Eggermont A., Kirkwood J., Cascinelli N., Markovic S.N., Hancock B., Lee S., Suciu S. on behalf of International Malignant Melanoma Collaborative Group: Interferon-{alpha} as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. ASCO Meeting Abstracts. 2007, v. 25 (18_suppl), p. 8526.
16. John M. Kirkwood, Catherine Bender, Sanjiv Agarwala, Ahmad Tarhini, Janice Shipe-Spotloe, Barbara Smelko, Sandra Donnelly, Lori Stover. Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy.
17. Vernon K. Sondak, Ricardo J. Gonzalez, Ragini Kudchadkar. Adjuvant Therapy for Melanoma: A Surgical Perspectivе. Surgical Oncology Clinics of North America. 2011, v. 20, p. 105-114.
18. Levesque N., Mitchinson K., Lawrie D., Fedorak L., MacDonald D., Normand C., Pouliot J. Benefits of hydration in patients receiving intron A therapy for high-risk melanoma: a nursing support program to minimize drug-related side effects Melanoma Research. 2006.
19. Демидов Л. В., Булавина И. С., Гладков О. А., Зинькевич М. В., Марочко А. Ю., Новик А. В. и соавт. Практические рекомендации по лекарственному лечению меланомы кожи. Злокачественные опухоли. 2015, No 4, спецвыпуск. С. 162-170.
Review
For citations:
Vichrova A.S., Orlova K.V., Samoylenko I.V., Kharkevich G.Yu., Demidov L.V. Tolerability of high-dose interferon alfa-2b in patients with high-risk melanoma. Bone and soft tissue sarcomas, tumors of the skin. 2016;(1):56-64. (In Russ.)
Views:
461
Email this article 
